Carillon Tower Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Carillon Tower Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$44.9M	Buy	+263,301	New	+$39M	0.27%	114
2020 Q3	–	Sell	-339,743	Closed	-$54.5M	–	485
2020 Q2	$54.5M	Hold	339,743	–	–	0.42%	76
2020 Q1	$31.6M	Hold	339,743	–	–	0.31%	116
2019 Q4	$43.8M	Hold	339,743	–	–	0.29%	119
2019 Q3	$25.6M	Sell	339,743 -190,932	-36%	-$22.5M	0.18%	207
2019 Q2	$80.6M	Sell	530,675 -82,535	-13%	-$10M	0.55%	40
2019 Q1	$80.6M	Sell	613,210 -215,827	-26%	-$27.7M	0.57%	29
2018 Q4	$90.5M	Buy	829,037 +11,121	+1%	+$1.39M	0.77%	12
2018 Q3	$132M	Buy	817,916 +295,582	+57%	+$40.4M	0.95%	6
2018 Q2	$69M	Sell	522,334 -173,570	-25%	-$16.4M	0.54%	42
2018 Q1	$50M	Hold	695,904	–	–	0.39%	76
2017 Q4	$38.7K	Buy	+695,904	New	+$36.9M	0.41%	85

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carillon Tower Advisers's SRPT Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in Sarepta Therapeutics (SRPT) in Q4 2020: 263,301 shares worth $44.9M. The stake represents 0.27% of the portfolio and ranks #114 among its holdings. This is a return to the name: Carillon Tower Advisers previously reported a position in SRPT as recently as Q2 2020.

Carillon Tower Advisers first reported a position in SRPT in Q4 2017 and has held it in 12 quarters since. The position peaked at $132M in Q3 2018. 454 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

Carillon Tower Advisers held 263,301 shares of Sarepta Therapeutics worth $44.9M as of Q4 2020.
Sarepta Therapeutics was a new Carillon Tower Advisers position in Q4 2020.
Sarepta Therapeutics made up 0.27% of Carillon Tower Advisers's portfolio in Q4 2020, its #114 holding.
Carillon Tower Advisers first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 12 quarters since.
Carillon Tower Advisers's Sarepta Therapeutics position peaked at $132M in Q3 2018.
454 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.